Patents by Inventor Pamela LAGALI

Pamela LAGALI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutical tools and methods for treating blindness
    Patent number: 10987404
    Abstract: The present invention relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 27, 2021
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: David Balya, Volker Busskamp, Pamela Lagali, Botond Roska
  • NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS
    Publication number: 20180125925
    Abstract: The present invention relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: November 13, 2017
    Publication date: May 10, 2018
    Applicant: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: David BALYA, Volker BUSSKAMP, Pamela LAGALI, Botond ROSKA
  • Retinal on bipolar cells-specific artificial promoter
    Patent number: 9862970
    Abstract: An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1, or a nucleic acid sequence of at least 1000 bp having at least 70% identity to the sequence of SEQ ID NO:1. The isolated nucleic acid molecule can lead to the expression of a gene in retinal ON bipolar cells when a nucleic acid sequence coding for a gene is operatively linked to the isolated nucleic acid molecule.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: January 9, 2018
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Botond Roska, Pamela Lagali
  • Therapeutical tools and methods for treating blindness
    Patent number: 9844579
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 19, 2017
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: David Balya, Volker Busskamp, Pamela Lagali, Botond Roska
  • RETINAL ON BIPOLAR CELLS-SPECIFIC ARTIFICIAL PROMOTER
    Publication number: 20160138043
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 by having at least 70% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in ON bipolar cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 19, 2016
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Botond ROSKA, Pamela LAGALI
  • Novel Therapeutical Tools and Methods for Treating Blindness
    Publication number: 20130059374
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 7, 2013
    Inventors: Volker BUSSKAMP, Pamela LAGALI, Botond ROSKA, Rita HABAR
  • Novel Therapeutical Tools and Methods for Treating Blindness
    Publication number: 20120258530
    Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.
    Type: Application
    Filed: November 18, 2011
    Publication date: October 11, 2012
    Inventors: David BALYA, Rita HABAR, Volker BUSSKAMP, Pamela LAGALI, Botond ROSKA